Chunhoo Cheon

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

Journal: Integrative cancer therapies
Published: August 04, 2026

Associations Between Meteorological Factors and Cardiac-Related Morbidity in Three South Korean Cities.

Associations Between Meteorological Factors and Cardiac-Related Morbidity in Three South Korean Cities.

Journal: Asia-Pacific journal of public health
Published: June 10, 2026

Changes in Health Behaviors During the COVID-19 Social Distancing Period in South Korea: A Nationwide Study.

Changes in Health Behaviors During the COVID-19 Social Distancing Period in South Korea: A Nationwide Study.

Journal: Behavioral medicine (Washington, D.C.)
Published: February 16, 2026

JI-CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7-H3.

JI-CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7-H3.

Journal: Cancer science
Published: December 24, 2025

Associations between dual use of combustible cigarettes and electronic nicotine delivery systems and allergic rhinitis: An analysis of KNHANES data.

Associations between dual use of combustible cigarettes and electronic nicotine delivery systems and allergic rhinitis: An analysis of KNHANES data.

Journal: The World Allergy Organization journal
Published: December 14, 2025

JI-CJ001 Enhances Paclitaxel Sensitivity in Gastric Cancer Cell Lines through Inhibition of HER2/mTOR Signaling and Induction of Autophagy.

JI-CJ001 Enhances Paclitaxel Sensitivity in Gastric Cancer Cell Lines through Inhibition of HER2/mTOR Signaling and Induction of Autophagy.

Journal: Anticancer research
Published: October 15, 2025

Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial.

Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial.

Journal: Integrative cancer therapies
Published: August 09, 2025

Combination of SH003 and paclitaxel modulates tumor microenvironment and inhibits metastasis of metastatic melanoma.

Combination of SH003 and paclitaxel modulates tumor microenvironment and inhibits metastasis of metastatic melanoma.

Journal: Medical oncology (Northwood, London, England)
Published: July 22, 2025

JI-CJ002, a Natural Herbal Formula, Enhances the Antitumor Efficacy of FOLFOX in Colorectal Cancer by Suppressing the DDR Pathway.

JI-CJ002, a Natural Herbal Formula, Enhances the Antitumor Efficacy of FOLFOX in Colorectal Cancer by Suppressing the DDR Pathway.

Journal: Anticancer research
Published: July 03, 2025

Trichosanthes kirilowii Maxim. and Bioactive Compound Cucurbitacin D Alleviate Cisplatin-Induced Peripheral Neuropathy In Vitro and In Vivo.

Trichosanthes kirilowii Maxim. and Bioactive Compound Cucurbitacin D Alleviate Cisplatin-Induced Peripheral Neuropathy In Vitro and In Vivo.

Journal: Integrative cancer therapies
Published: May 19, 2025

SH003 Inhibits Proliferation and Induces Apoptosis in Colon Cancer Through the RTK-STAT3 Pathway.

SH003 Inhibits Proliferation and Induces Apoptosis in Colon Cancer Through the RTK-STAT3 Pathway.

Journal: Anticancer research
Published: January 06, 2025

Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway.

Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway.

Journal: Scientific reports
Published: November 01, 2024
Showing 1-12 of 67

Last Updated: 09/26/2026